The US Food and Drug Administration’s proposal to regulate laboratory-developed tests (LDTs) will either ensure patients receive accurate results they can depend on for making critical health decisions, or it will cripple diagnostics leading to significant patient harm.
These divergent predictions represent the contrast of views that have flowed into the agency since it published its proposed rule on regulating LDTs in October. To date, the agency has...